Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to understand the bioenergetic impairments that underlie
Parkinson's disease (PD) and evaluating treatments that may improve abnormal mitochondrial
function that is present in PD. The hypothesis is that repeated oral dosing of UDCA will
result in increased brain ATP levels in individuals with Parkinson's disease (PD). The
specific aims are 1.) to measure plasma UDCA levels in individuals with PD at baseline and
after four weeks of repeated high doses of oral UDCA (50mg/kg/day) and 2.) to measure
cortical bioenergetic profile and ATPase activity (as ascertained through MRS) in those with
PD at baseline and at four weeks after repeated high doses of oral UDCA (50mg/kg/day)
simultaneously. Secondary aims are to characterize oral UDCA pharmacokinetics and develop a
pharmacokinetic/pharmacodynamic model to characterize the relationship between peripheral
measurements of UDCA (and associated conjugates) and peripheral measures and/or central
(brain) bioenergetic measurements.
Phase:
Phase 1
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute